In the UK, Advanced Accelerator Applications (AAA) has been granted a Promising Innovative Medicine (PIM) designation for 177Lu-PSMA-617, an investigational radioligand therapy.
The Novartis (NOVN: VX) company is a French nuclear medicines specialist, headquartered on the border with Switzerland, close to Geneva.
The UK’s medicines regulator, the Medicines and Healthcare Products Regulatory Agency (MHRA), granted the designation for the treatment of certain adults with prostate cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze